Margolis, David J. http://orcid.org/0000-0002-0506-8085
Mitra, Nandita http://orcid.org/0000-0002-7714-3910
Wubbenhorst, Bradley http://orcid.org/0000-0001-8489-3659
Nathanson, Katherine L. http://orcid.org/0000-0002-6740-0901
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH NIAMS R01-AR069062)
Article History
Received: 2 July 2019
Accepted: 13 July 2019
First Online: 1 August 2019
Compliance with ethical standards
:
: David Margolis had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. David Margolis receives research funding as the principal investigator via the Trustees of the University of Pennsylvania (R01-AR060962, R01-AR070873, and R01-DK116199) and from the NIH and Valeant Pharmaceuticals (PEER study) and Sunovion Pharmaceuticals. Only funding from R01-AR060962 of was used for this study. He has consulting activities primarily as a member of data monitoring boards or scientific advisory boards with Leo, Johnson and Johnson, Pfizer, Sanofi, Kerecis, and Cell Constructs. None of these activities are associated with the outcomes of this study. Authors Mitra, Wubbenhorst and Nathanson received research funding from R01-AR060962 and report no other authors report conflicts of interest.